Literature DB >> 28536305

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Emma Eriksson1, Ioanna Milenova1, Jessica Wenthe1, Magnus Ståhle1, Justyna Leja-Jarblad1,2, Gustav Ullenhag1,3, Anna Dimberg1, Raphael Moreno4, Ramon Alemany4, Angelica Loskog5,6.   

Abstract

Purpose: Pancreatic cancer is a severe indication with short expected survival despite surgery and/or combination chemotherapeutics. Checkpoint blockade antibodies are approved for several cancer indications, but pancreatic cancer has remained refractory. However, there are clinical data suggesting that stimulation of the CD40 pathway may be of interest for these patients. Oncolytic viruses armed with immunostimulatory genes represent an interesting approach. Herein, we present LOAd703, a designed adenovirus armed with trimerized CD40L and 4-1BBL that activates the CD40 and 4-1BB pathways, respectively. As many cells in the tumor stroma, including stellate cells and the infiltrating immune cells, express CD40 and some 4-1BB, we hypothesize that LOAd703 activates immunity and simultaneously modulates the biology of the tumor stroma.Experimental Design: Tumor, stellate, endothelial, and immune cells were infected by LOAd703 and investigated by flow cytometry, proteomics, and functional analyses.
Results: LOAd703-infected pancreatic cell lines were killed by oncolysis, and the virus was more effective than standard-of-care gemcitabine. In in vivo xenograft models, LOAd703 efficiently reduced established tumors and could be combined with gemcitabine for additional effect. Infected stellate and tumor cells reduced factors that promote tumor growth (Spp-1, Gal-3, HGF, TGFβ and collagen type I), while chemokines were increased. Molecules involved in lymphocyte migration were upregulated on infected endothelial cells. Dendritic cells were robustly stimulated by LOAd703 to produce costimulators, cytokines and chemokines, and such DCs potently expanded both antigen-specific T cells and NK cells.Conclusions: LOAd703 is a potent immune activator that modulates the stroma to support antitumor responses. Clin Cancer Res; 23(19); 5846-57. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28536305     DOI: 10.1158/1078-0432.CCR-17-0285

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC.

Authors:  Yonghui Zhang; Hailin Zhang; Mei Wei; Tao Mou; Tao Shi; Yanyu Ma; Xinyu Cai; Yunzheng Li; Jie Dong; Jiwu Wei
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

2.  Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis.

Authors:  Zipeng Lu; Maximilian Weniger; Kuirong Jiang; Stefan Boeck; Kai Zhang; Alexander Bazhin; Yi Miao; Jens Werner; Jan G D'Haese
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

3.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

Review 4.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

5.  Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination.

Authors:  Jon Amund Kyte; Anne Fåne; Martin Pule; Gustav Gaudernack
Journal:  Oncoimmunology       Date:  2019-01-19       Impact factor: 8.110

Review 6.  The emerging role of oncolytic virus therapy against cancer.

Authors:  Luke Russell; Kah-Whye Peng
Journal:  Chin Clin Oncol       Date:  2018-04

Review 7.  The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.

Authors:  Won Jin Ho; Elizabeth M Jaffee; Lei Zheng
Journal:  Nat Rev Clin Oncol       Date:  2020-05-12       Impact factor: 66.675

8.  Immune therapy, a double-edged sword for oncolytic viruses.

Authors:  Ryan M McCormack; Balveen Kaur
Journal:  Expert Opin Biol Ther       Date:  2019-08-06       Impact factor: 4.388

Review 9.  The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?

Authors:  Shunchuan Zhang; Samuel D Rabkin
Journal:  Expert Opin Drug Discov       Date:  2020-12-14       Impact factor: 6.098

Review 10.  Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses.

Authors:  Sakhawat Ali; Qin Xia; Tahir Muhammad; Liqun Liu; Xinyi Meng; David Bars-Cortina; Aamir Ali Khan; Yinghui Huang; Lei Dong
Journal:  Stem Cell Rev Rep       Date:  2021-07-28       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.